News
GlyTherix Ltd Announces Cyclowest Holdings as Cornerstone Investor and exclusive Manufacturing, Supply & Distribution partner for 89Zirconium
Sydney, Australia – July 22, 2023. GlyTherix Ltd (GlyTherix), an Australian immuno-oncology company specialising in developing antibody radiopharmaceuticals for solid tumours is pleased to announce a cornerstone investment by Cyclowest Holdings Pty Ltd (Cyclowest) in...
Key GlyTherix patent finalises in-country registration journey
GlyTherix is pleased to announce that our key composition of matter patent titled “Monoclonal Anti-GPC-1 antibodies and uses thereof” has now completed in-country registration. We now have protection in 21 countries including US, UK, Europe, China, Japan, and...
GPC-1 – a first-in-class “theranostic” oncology asset – The Evidence
Learn more about our Glypican-1 (GPC-1) antibody as a targeted therapy for delivering a radioactive payload to cancer cells. The evidence for GPC-1 being a key target in cancer therapy continues to expand rapidly. This includes recent publications with our...
GlyTherix Ltd signs Lutetium-177 supply agreement with ANSTO
ANSTO to supply Lutetium-177 for GlyTherix’s Phase Ib therapeutic trial in patients with prostate, pancreatic and bladder cancers Phase Ib basket clinical trial expected to start in late 2023 Sydney, Australia – February 21, 2023 – GlyTherix Ltd, an Australian...
GlyTherix seeks USD 10M in pre-IPO funding ahead of planned listing in 2024
February 10, 2023 – Thanks Mergermarket (an ION group company) for your cover of our exciting news “GlyTherix seeks USD 10m in pre-IPO funding ahead of planned listing in 2024 – CEO”. Our Phase 1b study will be a pivotal event for the company as we develop a vital new...
GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
December 20, 2022 – GlyTherix Ltd (“GlyTherix”), an Australian immuno-oncology company today announced an MTA & Option License with Adcendo ApS (“Adcendo”), a Danish biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the...
GlyTherix and The University of Queensland join forces in ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
GlyTherix Ltd today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland....
GlyTherix IP News
We are pleased to announce that our key composition of matter patent for GlyTherix Ltd’s proprietary antibody to GPC-1 is now registered in 20 countries including US, Australia, China and Japan as well as several key European countries. The company’s IP estate is...
High-Yield GMP-Compliant Primary Cell Bank Established for Miltuximab®
Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...
GlyTherix is a partner in ARC Hub for Advanced Manufacture of Targeted Radiopharmaceuticals
Congratulations to Prof Kris Thurecht for the funding of the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR). GlyTherix Ltd is a proud partner organisation and is excited to see Australian radioimmunotherapy technology getting this...
GlyTherix and GEMINI Collaborate on Esophageal Cancer
Date, July 8 2022: Sydney. GlyTherix has commenced an exciting new collaboration with the GastroEsophageal Malignancies Investigator Network Initiative (GEMINI) to test its Miltuximab® monoclonal antibody therapies in gastroesophageal cancers. GEMINI, backed by the...
GlyTherix awarded NSW Government TechVoucher to evaluate efficacy of our cancer antibody Miltuximab®
GlyTherix is pleased to announce the award of a $50,000 COVID-19 TechVoucher by the NSW Government through Investment NSW that will provide funding support to collaborate with ANSTO’s world-leading radiochemistry and preclinical imaging teams. Funds will be used to...
GlyTherix is a recipient of the first round of the TIA pipeline accelerator 2020-21 scheme
GlyTherix Ltd is proud to be a recipient of the first round of the Pipeline Accelerator 2020-21 scheme from Therapeutic Innovation Australia (TIA). Round 1 saw the award of $685,000 to 21 projects. Our project “Optimisation and characterisation of Miltuximab®-DFO...
Carina Biotech and GlyTherix enter into CAR-T partnership
PRESS RELEASE September 10, 2020 Adelaide, Australia and Sydney, Australia. CAR-T biotherapeutics company Carina Biotech and immuno-oncology company GlyTherix are pleased to announce a co-development agreement that could result in a promising new CAR-T therapy that is...
GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant
16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
Industry News: MTPConnect’s COVID-19 Impact Report
Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact Report.
Four New Peer Reviewed Papers Underline the Strength of the GlyTherix Technology
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...